Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

Go back to Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
Roche Holding AG Basel American Depositary Shares (AMEX: RHHBY) Delayed: 49.12 --0 (-0%)
Previous Close $49.12    52 Week High $35.13 
Open $49.12    52 Week Low $28.10 
Day High $49.12    P/E N/A 
Day Low $49.12    EPS $0.00 
Volume 112       

Brown & Brown, Inc. (NYSE: RO) Delayed: 8.49 +0.55 (6.93%)
Previous Close $7.94    52 Week High $8.59 
Open $7.94    52 Week Low $7.82 
Day High $8.59    P/E 6.53 
Day Low $7.82    EPS $1.30 
Volume 42,732       

Roper Industries (NASDAQ: ROP) Delayed: 325.09 --0 (-0%)
Previous Close $325.09    52 Week High $195.93 
Open $325.09    52 Week Low $155.79 
Day High $325.09    P/E 60.54 
Day Low $325.09    EPS $5.37 
Volume 534